The top 100 stock
market authors
selected for publication
market authors
selected for publication
Neuromics
»
Comments
» Single Comment
| 
Comments by Ticker
1 comment
Rating: 0
(0 
-
0 
)
-
0 )
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
TraderMark
-
2
Don Dion
-
3
Cliff Wachtel
-
4
Mike Havrilla
-
5
James Quinn
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
I concur with MKS.
Aug 26 02:59 am
|Rating:
0
0
All Comments by Neuromics »Alnylam and RNAi: The Truth Hurts [View article]
Yes there are issues with delivery as there are with antisense, another RNA based drug development platform. Despite this, Isis Pharmaceuticals, Inc's., an antisense based drug development company, stock is trading near its 52 week high with several Drugs in phase III. If several receive FDA approval this would bode well for ALNY.
At Neuromics, we have experience marketing antisense and siRNA based platforms for gene expression analysis research. siRNA delivered in cases where antisense failed.